Height Securities Sees FTC Approval of Walgreens (WBA)/Rite Aid (RAD) Deal
- Donald Trump Sworn in as 45th U.S. President
- Wall Street ends higher as Trump becomes president
- Walgreens Boots Alliance (WBA) Said to Face Antitrust Concern for Rite Aid (RAD) Fix - Bloomberg
- Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
- Apple (AAPL) Sues Qualcomm (QCOM) Over Patent Royalties in Antitrust Case - Bloomberg
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
Tracy commented, "We believe that the Rite Aid (RAD)/Walgreens (WBA) transaction will gain FTC approval and that market concerns are overblown. As we discussed in our August 3 report, the biggest antitrust risk comes from the FTC’s sufficiency determination. While the FTC has made statements about increased antitrust enforcement, we believe that the market definition process and potential remedies are well along in the RAD/WBA transaction. The FTC is most likely reviewing the transaction under a local market definition, and the extended timeline could be due to a number of related factors. Overall, we believe that there has been little change in antitrust risk to the transaction over the past few months."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Rite Aid (RAD)/Walgreens (WBA) Antitrust Concerns Doesn't Mean Deal is Dead, Says Deutsche Bank
- JPMorgan Cuts Teva Pharma (TEVA) to Neutral Amid Challenging Generic Environment
- Zayo Group Holdings (ZAYO) PT Raised to $41 at BTIG; Reiterates Buy
Create E-mail Alert Related CategoriesAnalyst Comments, Hot Comments, Mergers and Acquisitions, Rumors
Related EntitiesDefinitive Agreement
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!